Table 5.
Thromboembolic events according to Cisplatin-based chemotherapy regimen
| Chemotherapy Regimen | Patients | Thromboembolic Events | p-value | ||
|---|---|---|---|---|---|
| (n) | (%) | (n) | (%) | ||
| Cisplatin-Docetaxel-5FU | |||||
| Head and Neck | 95 | 38.8 | 0 | 0 | <0.0001 |
| Gastric | 136 | 55.5 | 28 | 20.6 | |
| Esophageal | 7 | 2.9 | 3 | 42.9 | |
| Others | 7 | 2.9 | 0 | 0 | |
| Total | 245 | 31 | 12.7 | ||
| Cisplatin-XRT | |||||
| Cervical | 101 | 33.8 | 7 | 6.9 | 0.2166 |
| Head and Neck | 184 | 61.5 | 5 | 2.7 | |
| Others | 14 | 4.7 | 1 | 7.1 | |
| Total | 299 | 13 | 4.3 | ||
| Cisplatin-Docetaxel | |||||
| Lung | 181 | 93.3 | 12 | 6.6 | 0.9999 |
| Others | 13 | 6.7 | 1 | 7.7 | |
| Total | 194 | 13 | 6.7 | ||
5FU 5-Flurouracil, XRT Radiation therapy